SEHK:2096Pharmaceuticals
Assessing Simcere Pharmaceutical Group’s Valuation After Strong Earnings And Positive SIM0237 Cancer Trial Results
Why Simcere’s latest earnings and cancer trial update matter for investors
Simcere Pharmaceutical Group (SEHK:2096) has just paired strong full year 2025 earnings with encouraging Phase I/II data for its bladder cancer therapy SIM0237, a combination that is drawing fresh attention from investors.
See our latest analysis for Simcere Pharmaceutical Group.
The latest 7.96% 1 day share price return to HK$12.07, alongside a 52.80% 1 year total shareholder return and solid multi year gains, points...